tbuckley/cabot-search huggingface dataset:
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Authors: Jerry R. Mendell, Samiah Al-Zaidy, Richard Shell, W. Dave Arnold, Louise R. Rodino-Klapac, Thomas W. Prior, Linda Lowes, Lindsay Alfano, Katherine Berry, Kathleen Church, John T. Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Jessica A. Cardenas, Marjet D. Heitzer, Allan Kaspar, Sarah Corcoran, Lyndsey Braun, Shibi Likhite, Carlos Miranda, Kathrin Meyer, K.D. Foust, Arthur H.M. Burghes, Brian K. Kaspar
Journal: New England Journal of Medicine (2017)

Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease.Fifteen patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the missing SMN protein. Three of the patients received a low dose (6.7×1013 vg per kilogram of body weight), and 12 received a high dose (2.0×1014 vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts).As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone.In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Myocardial Iron Deficiency in Hemodialysis-Dependent End-Stage Renal Disease Patients Undergoing Oral Iron Therapy
Authors: Hua-yan Xu, Zhi-gang Yang, Rui Li, Ke Shi, Yi Zhang, Zhen-lin Li, Chun-chao Xia, Wan-lin Peng, Qing-yong Chen, Ying-kun Guo
Journal: Journal of the American College of Cardiology (2017)
Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies
Authors: Kanit Bhukhai, Edouard de Dreuzy, Marie Giorgi, Charlotte Colomb, Olivier Negre, Maria Denaro, Béatrix Gillet-Legrand, Joëlle Cheuzeville, Anaïs Paulard, Hélène Trebeden-Negre, Suparerk Borwornpinyo, Karine Sii-Felice, Leila Maouche, Julian D. Down, Phillippe Leboulch, Emmanuel Payen
Journal: Molecular Therapy (2017)

Although gene transfer to hematopoietic stem cells (HSCs) has shown therapeutic efficacy in recent trials for several individuals with inherited disorders, transduction incompleteness of the HSC population remains a hurdle to yield a cure for all patients with reasonably low integrated vector numbers. In previous attempts at HSC selection, massive loss of transduced HSCs, contamination with non-transduced cells, or lack of applicability to large cell populations has rendered the procedures out of reach for human applications. Here, we fused codon-optimized puromycin N-acetyltransferase to herpes simplex virus thymidine kinase. When expressed from a ubiquitous promoter within a complex lentiviral vector comprising the βAT87Q-globin gene, viral titers and therapeutic gene expression were maintained at effective levels. Complete selection and preservation of transduced HSCs were achieved after brief exposure to puromycin in the presence of MDR1 blocking agents, suggesting the procedure's suitability for human clinical applications while affording the additional safety of conditional suicide.
Cancer incidences in selected eastern european countries: trends and analysis.
Authors: Ivan I. Herbey, Nataliya V. Ivankova
Journal: Cancer Research (2006)

5362   In Eastern Europe cancer incidences have dramatically increased after Chernobyl explosion in 1986. Depending on the spread of nuclear radiation different countries received different dozes of nuclear contamination. This paper investigates the trends in cancer incidences in four Eastern European countries (Belarus, Latvia, Estonia, and Slovakia) during three 5 year-periods: 1983-1987, 1988-1992, and 1993-1997. We used cancer incidences for these periods reported by the International Association of Cancer Registries. We also calculated annual incidences of cancer for 16 major cancer types and total cancer incidences per 100,000 for both genders. Data analysis included descriptive statistics, independent measures analysis of variance and mixed design analysis of variance. Steady growth of cancer incidences across the four countries is observed (Table). In 1993-1997, ten years after the Chernobyl accident, there was 3-8% increase in each country in comparison with the previous period and 7-9% increase in comparison with the first period. The most common cancer types for all four countries across all periods were breast, lung and stomach. No statistically significant main effect for country ( F  (3,60) = .433,  p  > .05) or country and period interaction ( F  (3,60) = .205,  p  > .05) were found. A statistically significant main effect for time period was present ( F  (1,60) = 36.008,  p  = .000). Protected paired samples  t -tests revealed all three periods significantly differed from each other. A statistically significant increase from 1983-1987 to 1988-1992 ( t  (63) = −2.834,  p   t  (63) = −4.384,  p  = .000), and from 1983-1987 to 1993-1997 ( t  (63) = −6.118,  p  = .000) was observed. No statistically significant main effect for country ( F  (3,376) = .917,  p  > .05), for gender ( F  (1,376) = .501,  p  > .05), and for country and gender interaction ( F  (3,376) = .189,  p  > .05) were found. Neither the country characteristics, nor gender differences had any statistically significant effect on the growth of cancer incidences during the three studied periods. Nuclear radiation is not the single factor causing increase of cancer incidences. Other environmental factors and their combination for each particular country need be considered.
TCT-264 Intracardiac Shunts Following Transcatheter Aortic Valve Implantation: A Multicentre Study
Authors: Ignacio Amat-Santos, Pieter Stella, Luis Nombela-Franco, Roman Lezaun, Antonio Munoz-Garcia, Vicente Serra, Enrique Gutiérrez, Ramon Rodríguez-Olivares, Silvio Vera, Pablo Catala, Itziar Gomez
Journal: Journal of the American College of Cardiology (2017)
Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology
Authors: Manuel A Ferreira, Judith M Vonk, Hansjörg Baurecht, Ingo Marenholz, Chao Tian, Joshua D Hoffman, Quinta Helmer, Annika Tillander, Vilhelmina Ullemar, Jenny van Dongen, Yi Lu, Franz Rüschendorf, Jorge Esparza-Gordillo, Chris W Medway, Edward Mountjoy, Kimberley Burrows, Oliver Hummel, Sarah Grosche, Ben M Brumpton, John S Witte, Jouke-Jan Hottenga, Gonneke Willemsen, Jie Zheng, Elke Rodríguez, Melanie Hotze, Andre Franke, Joana A Revez, Jonathan Beesley, Melanie C Matheson, Shyamali C Dharmage, Lisa M Bain, Lars G Fritsche, Maiken E Gabrielsen, Brunilda Balliu, Jonas B Nielsen, Wei Zhou, Kristian Hveem, Arnulf Langhammer, Oddgeir L Holmen, Mari Løset, Gonçalo R Abecasis, Cristen J Willer, Andreas Arnold, Georg Homuth, Carsten O Schmidt, Philip J Thompson, Nicholas G Martin, David L Duffy, Natalija Novak, Holger Schulz, Stefan Karrasch, Christian Gieger, Konstantin Strauch, Ronald B Melles, David A Hinds, Norbert Hübner, Stephan Weidinger, Patrik K E Magnusson, Rick Jansen, Eric Jorgenson, Young-Ae Lee, Dorret I Boomsma, Catarina Almqvist, Robert Karlsson, Gerard H Koppelman, Lavinia Paternoster
Journal: Nature Genetics (2017)
Abstract 11498: MicroRNA 140 Regulates Disease Phenotype in Experimental Pulmonary Arterial Hypertension And Identifies Smurf1 as a Novel Therapeutic Target
Authors: Alexander M Rothman, Nadine D Arnold, Josephine A Pickworth, James Iremonger, Loredana Ciuclan, Robert Allen, Sabine Guth-Gundel, Mark Southwood, Nicholas W Morrell, Sheila E Francis, David Rowlands, Allan Lawrie
Journal: Circulation (2015)

Rationale: Clinical therapies for the treatment of pulmonary arterial hypertension (PAH) target vasoconstriction. However, the proliferative pulmonary vascular remodelling that drives disease persists contributing to significant patient morbidity and mortality. MicroRNA (miR) are short non-coding RNA that mediate post-transcriptional regulation of mRNA targets. We hypothesise that dysregulation of miR leads to de-repression of cellular targets central to disease pathogenesis. Objective: To identify dysregulated circulating miR in patients with PAH, determine their phenotypic effect using in vitro and in vivo models and identify key mechanistic regulators that may represent novel therapeutic targets. Methods and Results: Expression of miR-140 was reduced in whole blood samples from patients with PAH and the monocrotaline (Mct) and Sugen5416 plus Hypoxia (SuHx) rat models of PAH. Reduced expression of miR-140 at the time of diagnosis identified patients with adverse clinical outcome. Network and pathway analysis identified key regulators of TGFß and PDGF signalling as miR-140 targets. Transfection with miR-140 inhibitor resulted in increased proliferation and migration of PASMC and de-repression of key targets. Nebulised delivery of miR-140 mimic prevented the development of PAH in the Mct rat model and attenuated progression of established PAH in the Mct and SuHx rat models. SMAD Specific E3 Ubiquitin Protein Ligase 1 (SMURF1) mRNA and protein was decreased in the lungs of miR-140 mimic treated animals. Levels of SMURF1 protein correlated inversely with miR-140. Direct regulation of SMURF1 by miR-140 was demonstrated in vitro by 3’UTR luciferase activity. Both miR-140 mimic and SMURF1 siRNA increased BMP response element activity identifying SMURF1 as a key negative regulator of BMP signalling in PASMC. Genetic ablation of SMURF1 in C57BL6 mice conferred allele dependent protection from SuHx induced PAH. Finally, whole blood mRNA and pulmonary vascular immunoreactivity of SMURF1 was increased in patients with PAH. Conclusions: These studies suggest that miR-140 and SMURF1 are key regulators of BMP signaling and disease pathology in PAH and highlight SMURF1 as a potential novel therapeutic target.
TCT-650 Higher levels of matured PCSK9 is associated with coronary spotty calcification in patients with Acute Coronary Syndromes
Authors: Mami Watanabe, Raisuke Iijima, Norihiro Kogame, Fumiyuki Hayashi, Masahide Tokue, Tsuyoshi Ono, Hidehiko Hara, Masato Nakamura
Journal: Journal of the American College of Cardiology (2017)
Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis
Authors: Eldad Zacksenhaus, Mariusz Shrestha, Jeff C. Liu, Ioulia Vorobieva, Philip E.D. Chung, YoungJun Ju, Uri Nir, Zhe Jiang
Journal: Trends in cancer (2017)
Phage Therapy’s Role in Combating Antibiotic-Resistant Pathogens
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nouvelles tendances des hépatites virales aiguës rencontrées par les médecins généralistes belges
Authors: D Devroey, V van Casteren, R Vranckx
Journal: Eurosurveillance (1997)

En Belgique, le reseau sentinelle de medecins generalistes fontionne depuis 1979 et surveille un large eventail de maladies, infectieuses ou non (1,2). De tels systemes de surveillance ont deja ete testes et consideres comme efficaces (3,4) ; ils existent actuellement dans plusieurs pays (5). La premiere etude du reseau sentinelle sur l'incidence de l'hepatite virale aigue symptomatique a ete effectuee entre 1982 et 1984 (6,7). Les cas cliniques etaient investigues par le Centre National des Hepatites Virales qui analysait les echantillons sanguins des patients presentant un diagnostic clinique de suspicion d'hepatite virale aigue (8). Les resultats de laboratoire ont ete extrapoles a l'ensemble de la population belge pour estimer l'incidence des differents types d'hepatite virale aigue (9).
Unusual Uptake of 131I in a Cutaneous Benign Fibrous Histiocytoma in a Patient With Thyroid Cancer
Authors: Huijun Zhou, Jiaqi Yan, Rui Huang, Lin Li
Journal: Clinical Nuclear Medicine (2017)

A 52-year-old man with papillary thyroid cancer underwent total thyroidectomy and subsequent I remnant ablation. The postablation whole-body radioiodine scanning showed an unexpected focus on the upper right arm. SPECT/CT found that the abnormal focus of radioactivity was from body surface. Histopathology confirmed the diagnosis of benign fibrous histiocytoma.
Role of Sexuality in the Outcome of Anorexia Nervosa and Bulimia Nervosa: A 3-Year Follow-Up Study
Authors: Giovanni Castellini, Lorenzo Lelli, Elisa Corsi, Beatrice Campone, Eleonora Ciampi, Alessandra D. Fisher, Luca Mallardo, Alessio Maria Monteleone, Francesco Rotella, Tommaso Tofani, Linda Vignozzi, Francesco Zamponi, Mario Maggi, Valdo Ricca
Journal: Psychotherapy and Psychosomatics (2017)
Sixty seconds on . . . bioelectronics
Authors: Ann Robinson
Journal: BMJ (2017)

Well, it’s new and exciting, but it’s not a major blockbuster movie. It’s actually a new scientific field developing miniaturised, implantable devices that could replace pills or injections in the future.

The vision is that the devices will be smaller than a grain of sand.

No. But bigger implantable devices are already in use.

Vagal nerve stimulation (VNS),1 which uses periodic electrical signals from a pulse generator to stimulate the vagus nerve.

Yes, similar. The patient has a local or general anaesthetic and an incision …
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas, Ivo Kwee, Petra Hillmann, Andrea Rinaldi, Luciano Cascione, Filippo Spriano, Elena Bernasconi, Francesca Guidetti, Laura Carrassa, Roberta Bordone Pittau, Florent Beaufils, Reto Ritschard, Denise Rageot, Alexander Sele, Barbara Dossena, Francesca Maria Rossi, Antonella Zucchetto, Monica Taborelli, Valter Gattei, Davide Rossi, Anastasios Stathis, Georg Stussi, Massimo Broggini, Matthias P. Wymann, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients. Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR inhibitor under clinical evaluation, in preclinical lymphoma models. Experimental Design: This study included preclinical in vitro activity screening on a large panel of cell lines, both as single agent and in combination, validation experiments on in vivo models and primary cells, proteomics and gene-expression profiling, and comparison with other signaling inhibitors. Results: PQR309 had in vitro antilymphoma activity as single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab. Sensitivity to PQR309 was associated with specific baseline gene-expression features, such as high expression of transcripts coding for the BCR pathway. Combining proteomics and RNA profiling, we identified the different contribution of PQR309-induced protein phosphorylation and gene expression changes to the drug mechanism of action. Gene-expression signatures induced by PQR309 and by other signaling inhibitors largely overlapped. PQR309 showed activity in cells with primary or secondary resistance to idelalisib. Conclusions: On the basis of these results, PQR309 appeared as a novel and promising compound that is worth developing in the lymphoma setting. Clin Cancer Res; 24(1); 120–9. ©2017 AACR.
Los Staphylococcus aureus resistentes a la meticilina en hospitales alemanes desarrollan patrones de resistencia más estrechos
Authors: W Witte, C Braulke, D Heuck, C Cuny
Journal: Eurosurveillance (2000)

Mientras la prevalencia de Staphylococcus aureus resistentes a la meticilina (SARM) sigue aumentando en los hospitales alemanes, la gama de antimicrobianos a la que son resistentes disminuye. Esta tendencia no se debe a cambios en el consumo de antibioticos. Es necesario que las medidas de aislamiento de los pacientes portadores de SARM sean respetadas.
A case of liver metastases with hyperbilirubinemia that was safely treated with chemotherapy (FOLFOX plus Cetuximab)
Authors: Setsuo Utsunomiya, Akihiko Okumura, Kazumasa Watanabe, Shin Kunii, Daisuke Ishikawa, Takuya Hirosaki, Kentarou Yamada, Atsurou Kaga
Journal: Annals of Oncology (2017)
Treating Depression in Patients With Advanced CKD
Authors: Carl P. Walther, Asim A. Shah, Wolfgang C. Winkelmayer
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea
Authors: Yu Ri Woo, Jong Sic Kim, Ji Hong Lim, Sewon Hwang, Miri Kim, Jung Min Bae, Young Min Park, Chang-Ki Min, Dong-Wook Kim, Hyun Jeong Park
Journal: Journal of the American Academy of Dermatology (2017)
TCT-372 Clinical Outcomes of Deferred Lesions with Angiographically Insignificant Stenosis but Low Fractional Flow Reserve
Authors: Joo Myung Lee, Bon-Kwon Koo, Eun-Seok Shin, Chang-Wook Nam, Joon-Hyung Doh, Xinyang Hu, Fei Ye, Shaoliang Chen, Junqing Yang, Jiyan Chen, Nobuhiro Tanaka, Hiroyoshi Yokoi, Hitoshi Matsuo, Hiroaki Takashima, Yasutsugu Shiono, Doyeon Hwang, Jonghanne Park, Takashi Akasaka, Jianan Wang
Journal: Journal of the American College of Cardiology (2017)
Red Europea de Vigilancia Serológica
Authors: K Osborne, J Weinberg, E Miller
Journal: Eurosurveillance (1997)

El objetivo de la vigilancia serologica es controlar el grado de inmunidad de una poblacion frente a ciertas enfermedades, con el fin de mejorar la calidad de las informaciones sobre las que se basan las medidas de salud publica como las campanas de vacunacion. En 1987, se puso en marcha una vigilancia serologica para controlar los efectos de una nueva campana de vacunacion contra el sarampion, parotiditis y rubeola (SPR) en Inglaterra y Pais de Gales (1). La identificacion de un aumento de la proporcion de ninos en edad escolar susceptibles de contraer el sarampion demuestra el interes de esta vigilancia. A partir de esta observacion, tecnicas de modelizacion matematica permitieron predecir una epidemia importante de sarampion en esos ninos (2). Estas previsiones estuvieron reforzadas por argumentos epidemiologicos procedentes de otras fuentes. Como resultado de tales previsiones, se organizo en 1994 una campana de vacunacion nacional para proteger a estos ninos (3).
TCT-560 Paclitaxel-Eluting Balloon versus conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery. The ISAR-PEBIS randomized trial
Authors: Theresa Wittmann, Salvatore Cassese, Philipp Groha, Birgit Steppich, Felix Voll, Martin Hadamitzky, Tareq Ibrahim, Sebastian Kufner, Karl Dewitz, Markus Kasel, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati, Massimiliano Fusaro, Ilka Ott
Journal: Journal of the American College of Cardiology (2017)
L'épidémiologie des infections à méningocoque en Angleterre et au Pays de Galles en 1996 et 1997
Authors: M E Ramsay, M Collins, M Rush, E Kaczmarksi
Journal: Eurosurveillance (1997)

La surveillance des infections a meningocoque en Angleterre et au Pays de Galles repose sur trois sources de donnees. Les medecins ont l'obligation de declarer au responsable local du controle des maladies transmissibles les cas cliniques de meningites a meningocoque et, depuis 1989, les cas de septicemie a meningocoque (en l'absence de meningite).
TCT-735 Impact of Stent overlapping on 5-year Clinical Outcomes of Patients undergoing Percutaneous Coronary Intervention using Second Generation Drug-eluting Stents
Authors: Ahmed Mashaly, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Won Young Jang, Woo Hyeun Kim, Eun Jin Park, Ja Yeon Choi, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)